Objective: We assessed clinical effectiveness, longevity of treatment effects, and patient satisfaction with incobotulinumtoxinA for glabellar frown lines (GFL) treatment in Asian patients.
by Hamzah Mustak, MD; Michael Rafaelof, BS; Robert Alan Goldberg, MD; and Daniel Rootman, MD Drs. Mustak, Goldberg, and Rootman and Mr. Rafaelof are with the Stein Eye Institute, Division of Orbital and Oculoplastic Surgery at the University of California, Los Angeles in Los Angeles, California. Dr. Mustak is also with the Groote Schuur Hospital,
by Gabriele F. Muti, MD, and Matteo Basso, MD Dr. Muti is with the Department of Plastic Surgery, European Dermatological Institute, in Milan, Italy. Dr. Basso is with the Studio Dermatologico in Rome, Italy. Funding: No funding was provided for this study. Disclosures: Dr. Muti has been an investigator and speaker for Merz Pharmaceuticals GmbH
by Yates Y.Y. Chao, MD; Chiranjiv Chhabra, MBBS, DVD; Niamh Corduff, MBBS, FRACS; Sabrina Guillen FABI, MD; Martina Kerscher, MD; Stephanie C.K. Lam, MBChB; Tatjana Pavicic, MD; Berthold Rzany, MD, ScM; Peter H.L. Peng, MD; Atchima Suwanchinda, MD; Fang-Wen Tseng, MD; and Kyle K. Seo, MD, PhD Dr. Chao is with Chao and Chiu Institute
by Dawnielle C. Endly, DO, and Richard A. Miller, DO Dr. Endly is with Advanced Dermatology Skin Cancer and Laser Surgery Center in Aurora, Colorado. Dr. Miller is with Nova Southeastern University/Largo Medical Center, Dermatology Residency Program and Bay Dermatology and Cosmetic Surgery in Largo, Florida. J Clin Aesthet Dermatol. 2017;10(8):49–55 Funding: No funding was